Emerging Markets Earnings Roundup: Abbott Laboratories, Novartis (Part 1)
This article was originally published in PharmAsia News
Executive Summary
Abbott and Novartis talk at length in quarterly earning calls on emerging markets as key to the fortunes of both companies. China again dominated the subject, but chief executives at both firms say the rapid pace of change in the country’s health sector remains a singular opportunity that means the only option is to double down on efforts to overcome regulatory and other hurdles.
You may also be interested in...
A Year After Chinese Health Authorities Vow To Rid Country Of Deliberately Adulterated Milk, A New Melamine Scandal Surfaces
BEIJING - One year after 11 Chinese ministries unveiled a massive program to ensure that the poison melamine was purged from national milk supplies, details are emerging of a new scandal involving the toxic chemical, along with a new government-aided cover-up in the rich coastal city of Shanghai
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.